Timothy Davis Jr.
About Timothy E. Davis, Jr.
Timothy E. Davis, Jr. is SI-BONE’s Lead Independent Director (age 55) and has served on the Board since the company’s inception in April 2008. He is President & CEO of BioTissue Holdings Inc. (since Jan 2022), and previously led Active Implants (2017–2021) and MicroPort Orthopedics (2014–2015) after senior roles at Wright Medical Technology; earlier he was a partner at MB Venture Partners and an investment professional at Vector Fund Management. He holds a B.E. in Biomedical Engineering from Vanderbilt University and an MBA from Northwestern’s Kellogg School of Management .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| SI-BONE, Inc. | Lead Independent Director; Director since inception | 2008–present | Lead Independent Director; chairs Compensation Committee; member of Audit Committee; designated audit committee financial expert . |
| BioTissue Holdings Inc. (private) | President & CEO | Jan 2022–present | Executive leadership in medical products; external role (no related-party transactions disclosed) . |
| Active Implants, LLC | President & CEO | Feb 2017–Dec 2021 | Orthopedic implant leadership . |
| MicroPort Orthopedics, Inc. | Chief Executive Officer | Jan 2014–Sep 2015 | Led post-acquisition integration of Wright Medical Group’s OrthoRecon business . |
| Wright Medical Technology, Inc. | Multiple executive roles incl. President, OrthoRecon | Dec 2006–Jan 2014 | P&L/operations in ortho devices . |
| MB Venture Partners, LLC | Partner | 2004–2006 | Medtech/life sciences venture capital . |
| Vector Fund Management | Investment professional (ultimately VP) | 1997–2004 | Healthcare/life sciences investing . |
External Roles
| Organization | Role | Public/Private | Notes |
|---|---|---|---|
| BioTissue Holdings Inc. | President & CEO | Private | Birth tissue-based products; ocular/surgical focus . |
| Other public company boards | — | — | No current public company directorships disclosed for Mr. Davis . |
Board Governance
| Attribute | Detail |
|---|---|
| Independence | Board determined Mr. Davis is independent under Nasdaq rules . |
| Lead Independent Director | Serves as Lead Independent Director; coordinates agendas and committee work to ensure effective functioning of the Board . |
| Committees (2024) | Compensation Committee – Chair; Audit Committee – Member; Nominating & Corporate Governance – not listed as member . |
| Financial Expertise | Board designated Mr. Davis as an “audit committee financial expert” . |
| Board/Committee Meetings | Board met 4 times in 2024; each director attended ≥75% of aggregate Board and committee meetings . |
| Annual Meeting Attendance | Seven directors attended the 2024 annual meeting; Mr. Davis was unable to attend . |
| Skills Matrix Highlights | Medical device industry; M&A; regulatory/clinical; risk/compliance; human capital; global business experience . |
Fixed Compensation
| Component | Amount/Policy | Evidence |
|---|---|---|
| 2024 Cash Fees (actual) | $75,000 | Director compensation table . |
| Policy – Board annual retainer | $45,000 (non-employee directors) | Non-employee director compensation policy . |
| Policy – Committee chair/member | Compensation Chair: $15,000; Audit Member: $10,000; Nominating Chair: $10,000; Nominating Member: $5,000 | Policy schedule . |
| Policy – Lead Independent Director stipend | $5,000 | Policy schedule . |
Note: Mr. Davis’ roles (Lead Independent Director; Compensation Chair; Audit Member) align with policy fee components; the sum of applicable policy amounts equals his 2024 cash fees, but the company reports only the total cash paid of $75,000 .
Performance Compensation
| Component | Detail | Evidence |
|---|---|---|
| 2024 Stock Awards (grant-date fair value) | $109,712 | Director compensation table . |
| Annual equity policy | Continuing non-employee directors may receive RSUs valued at $120,000 at each annual meeting; vest ~1 year | Policy description . |
| Initial equity policy | New directors receive RSUs valued at $250,000; vest ratably over 36 months | Policy description . |
| Vesting acceleration (Change in Control) | Unvested director equity fully vests immediately prior to a change in control, subject to continuous service | Policy description . |
| Performance metrics | Director RSUs are time-based (no performance metrics tied to director equity) | Policy description . |
Other Directorships & Interlocks
| Item | Status |
|---|---|
| Current public company directorships | None disclosed for Mr. Davis . |
| Compensation Committee interlocks | None; no executive officer of SI-BONE served on another company’s board/compensation committee with a SI-BONE director in 2024 . |
| Related-party transactions | None >$120,000 since start of FY2024; Audit Committee oversees policy . |
Expertise & Qualifications
- Biomedical engineering and medtech operating executive with CEO experience across orthopedics and surgical products; venture investing background .
- Audit committee financial expert; deep exposure to compensation matters; governance leadership as Lead Independent Director .
- Board skills matrix flags strengths in medical device industry, M&A, regulatory/clinical, risk/compliance, human capital, and global business .
Equity Ownership
| Metric | Figure | Date/Notes |
|---|---|---|
| Shares owned directly/indirectly | 38,606 | As of Mar 31, 2025 . |
| Right to acquire within 60 days | 54,893 | As of Mar 31, 2025 . |
| Total beneficial ownership | 93,499 | <1% of outstanding shares . |
| Options outstanding (12/31/2024) | 50,027 | Non-employee director outstanding awards table . |
| RSUs outstanding (12/31/2024) | 13,657 | Non-employee director outstanding awards table . |
| Hedging/Pledging | Prohibited for directors under Insider Trading Policy and Governance Guidelines . | |
| Ownership Guidelines | Directors expected to hold ≥3x annual Board cash retainer within 5 years; as of FY2024 end, all non-employee directors had satisfied or were on track | Guidelines and status . |
Governance Assessment
- Independence and leadership: Independent under Nasdaq, serves as Lead Independent Director, chairs Compensation Committee, and is an audit committee financial expert—positive for board oversight depth .
- Engagement: Attended ≥75% of Board/committee meetings in 2024 (company-wide threshold met), though he did not attend the 2024 annual meeting; monitor future annual meeting attendance as a soft signal .
- Pay alignment and ownership: Director pay mix includes equity; stock ownership guidelines and hedging/pledging prohibitions support alignment; no related-party transactions disclosed .
- Investor signals: Say-on-pay approval at ~98.3% in 2024 indicates broad shareholder support for compensation governance; Compensation Committee uses an independent consultant and conducts risk assessments .
RED FLAGS: None material identified. Notable watch item: missed 2024 annual meeting despite meeting attendance requirements .